MyoKardia Profile

62.80
USD 1.15  1.87%
61%
10%

Sale by Jake Bauer of 3101 shares of MyoKardia

MyoKardia insider trading alert for sale of common stock by Jake Bauer, Chief Business Officer, on September 16, 2018. This event was filed by Myokardia Inc with SEC on 2018-07-25. Statement of changes in beneficial ownership - SEC Form 4. Jake Bauer is currently serves as vice president - business development and business operations of MyoKardia [view details]   

MyoKardia Summary

MyoKardia (MYOK) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 147 people. MyoKardia is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 2.44 B. MyoKardia conducts business under Healthcare sector and is part of Biotechnology industry. This company has 40.12 M outstanding shares of which 2.37 M shares are now shorted by private and institutional investors with about 10.03 trading days to cover. MyoKardia currently holds about 398.59 M in cash with (55.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.94.
Check MyoKardia Probability Of Bankruptcy

Ownership Allocation (%)

MyoKardia Target Price Odds Analysis

Odds Below 62.8HorizonTargetOdds Above 62.8
90.59%30 days 62.80 9.24%
Based on normal probability distribution, the odds of MyoKardia to move above current price in 30 days from now is about 9.24% (This MyoKardia probability density function shows the probability of MyoKardia Stock to fall within a particular range of prices over 30 days) .

MyoKardia Top Holders

MyoKardia Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

MyoKardia Key Fundamentals

MyoKardia Against Markets

MyoKardia Current Ratings

MyoKardia 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
9 
Chance of
Financial Distress (0 to 100%)
27 
Equity ratings for MyoKardia are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California. MyoKardia operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 147 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
MyoKardia SEC Filings
MyoKardia SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameMyoKardia
CEO and President and DirectorTassos GianakakosView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCALIFORNIA U.S.A
Business Address333 Allerton Avenue
ExchangeBATS Exchange
CIK Number0001552451
CUSIP62857M105
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.myokardia.com
Phone650 741 0900
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestAugust 15, 2018

MyoKardia Directors

MyoKardia Corporate Directors

Eric Topol Independent Director
Sunil Agarwal Independent Director
Mark Perry Independent Director
Please see also Stocks Correlation. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.
Search macroaxis.com